Applying the OMOP Common Data Model to Facilitate Benefit-Risk Assessments of Medicinal Products Using Real-World Data from Singapore and South Korea.
Healthc Inform Res
; 28(2): 112-122, 2022 Apr.
Article
in En
| MEDLINE
| ID: mdl-35576979
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
Healthc Inform Res
Year:
2022
Document type:
Article
Affiliation country:
Country of publication: